Elodie Rosencher-Regnier
Paris, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
A fifth subtype of Kaposi's sarcoma, classic Kaposi's sarcoma in men who have sex with men: a cohort study in Paris.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: September 12, 2017
BRAF V600 inhibitor discontinuation after complete response in advanced melanoma: a retrospective analysis of 16 patients.
Journal: The British journal of dermatology
Published: January 28, 2017
Age and clear eyes are associated with an increased risk of cutaneous squamous cell carcinomas in vemurafenib-treated melanoma patients.
Journal: Melanoma research
Published: June 05, 2016
First-line treatment with paclitaxel for non-HIV-related Kaposi sarcoma: experience in 10 cases.
Journal: The British journal of dermatology
Published: October 20, 2015
Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma.
Journal: Targeted oncology
Published: July 26, 2015
Do anti-hypertensive renin-angiotensin system inhibitors contribute to the development of classical Kaposi sarcoma?
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: April 09, 2015
Late occurrence of Histoplasma duboisii cutaneous and pulmonary infection 18 years after exposure.
Journal: Journal de mycologie medicale
Published: May 01, 2014
Acute kidney injury in patients with severe rash on vemurafenib treatment for metastatic melanomas.
Journal: The British journal of dermatology
Published: May 28, 2013
Subacute cutaneous lupus erythematosus induced and exacerbated by proton pump inhibitors.
Journal: Dermatology (Basel, Switzerland)
Published: July 31, 2012
Treatments for classic Kaposi sarcoma: a systematic review of the literature.
Journal: Journal of the American Academy of Dermatology
Published: December 19, 2011
Factors associated with severe skin infections in patients treated with biologic therapies for inflammatory rheumatic diseases.
Journal: Dermatology (Basel, Switzerland)
Published: November 01, 2011
Last Updated: 09/26/2026